Background
ELEVATE-TN was a phase III randomized open-label three-arm trial evaluating acalabrutinib (a more selective second-generation BTK inhibitor) with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive CLL. It addressed two questions simultaneously: whether acalabrutinib monotherapy was superior to ClbO, and whether adding obinutuzumab to acalabrutinib (AO) further improved outcomes. The trial enrolled patients regardless of fitness, including both fit and unfit CLL patients.
Interventions and follow up
Arm A (ClbO): Chlorambucil 0.5 mg/kg days 1, 15 + obinutuzumab 1000 mg cycles 1–6 (n=177)
Arm B (AO): Acalabrutinib 100 mg PO BID + obinutuzumab 1000 mg cycles 2–7 → acalabrutinib continued until progression (n=179)
Arm C: Acalabrutinib 100 mg PO BID until progression (monotherapy) (n=179)
Primary endpoint: PFS (AO vs ClbO); secondary: acalabrutinib mono vs ClbO, OS, ORR, MRD, safety
mFollow up: 58.2 months (5-year update)
Arm B (AO): Acalabrutinib 100 mg PO BID + obinutuzumab 1000 mg cycles 2–7 → acalabrutinib continued until progression (n=179)
Arm C: Acalabrutinib 100 mg PO BID until progression (monotherapy) (n=179)
Primary endpoint: PFS (AO vs ClbO); secondary: acalabrutinib mono vs ClbO, OS, ORR, MRD, safety
mFollow up: 58.2 months (5-year update)
Results
5-yr PFS (AO vs ClbO): 62.3% vs 16.5%, HR 0.10, P<.0001
5-yr PFS (acalabrutinib mono vs ClbO): 60.5% vs 16.5%, HR 0.22, P<.0001
5-yr OS: AO 88.5%, acalabrutinib 88.8%, ClbO 83.0% (not significantly different)
ORR: AO 93.9%, acalabrutinib 85.5%, ClbO 78.5%
Undetectable MRD (peripheral blood, 10⁻⁴): AO 39.5%, acalabrutinib 7.8%, ClbO 9.7%
5-yr PFS (acalabrutinib mono vs ClbO): 60.5% vs 16.5%, HR 0.22, P<.0001
5-yr OS: AO 88.5%, acalabrutinib 88.8%, ClbO 83.0% (not significantly different)
ORR: AO 93.9%, acalabrutinib 85.5%, ClbO 78.5%
Undetectable MRD (peripheral blood, 10⁻⁴): AO 39.5%, acalabrutinib 7.8%, ClbO 9.7%
Adverse events
Hematologic (Grade ≥3 neutropenia): AO 31%, acalabrutinib 10%, ClbO 43%
Cardiovascular: atrial fibrillation all grades AO 5%, acalabrutinib 4%, ClbO 3% (markedly less AF than ibrutinib ~10–15%); hypertension <5%; major bleeding 2–3%
Other: headache (acalabrutinib class effect) 35–38% all grades, Grade ≥3 <1%; arthralgias/myalgias 15–20%; second primary malignancies ~5–7%
Cardiovascular: atrial fibrillation all grades AO 5%, acalabrutinib 4%, ClbO 3% (markedly less AF than ibrutinib ~10–15%); hypertension <5%; major bleeding 2–3%
Other: headache (acalabrutinib class effect) 35–38% all grades, Grade ≥3 <1%; arthralgias/myalgias 15–20%; second primary malignancies ~5–7%
Conclusions
Both acalabrutinib + obinutuzumab and acalabrutinib monotherapy significantly prolonged 5-year PFS versus chlorambucil-obinutuzumab (HR 0.10 and 0.22, respectively) in treatment-naive CLL, establishing acalabrutinib-based regimens as preferred first-line options with a markedly improved cardiovascular safety profile (especially reduced atrial fibrillation) compared with first-generation ibrutinib.
Key Limitations
ClbO comparator is suboptimal versus venetoclax + obinutuzumab (CLL14) or ibrutinib-based regimens (RESONATE-2); no head-to-head comparison to ibrutinib or venetoclax combinations; OS not improved versus ClbO, likely due to effective salvage after crossover; AO vs acalabrutinib monotherapy (the clinically relevant question) was not a pre-specified primary comparison; continuous BTKi therapy vs fixed-duration VenO not directly compared; atrial fibrillation still ~4–5%; del17p/TP53-mutant subgroup retains benefit but with inferior absolute outcomes.
Clinical Context
ELEVATE-TN supported FDA approval of acalabrutinib ± obinutuzumab for 1L CLL (November 2019). The head-to-head ASPEN trial (Waldenstrom) and ALPINE trial (R/R CLL) together established that next-generation BTKi (acalabrutinib, zanubrutinib) have superior cardiac safety to ibrutinib. ESMO and iwCLL guidance support acalabrutinib ± obinutuzumab across 1L CLL subgroups. The AMPLIFY trial (acalabrutinib + venetoclax ± obinutuzumab vs chemoimmunotherapy) represents the next generation of fixed-duration BTKi + BCL-2 combination strategies building on ELEVATE-TN's acalabrutinib foundation.